Pharma Pulse: 340B Uncertainty, Drug Shortages
Decision brief
Answer first · skim in under a minute
A Bluesight survey highlights hospital pharmacy anxieties over 340B program uncertainty and ongoing drug shortages. Meanwhile, Novo Nordisk launches the Wegovy pill in the UAE, signaling a global expansion strategy amid supply challenges.
Pharma Pulse 340B Uncertainty Drug coverage this cycle turns on three primary threads: CMS’s 2026 Part D 340B exclusion methodology, IRA rebate relief tied to FDA shortage lists, and post-shortage Wegovy labeling. Hospital pharmacy and manufacturer finance teams should track the federal texts, not secondary roundups.
Contents9 sections
Key Takeaways
- CMS finalized claims-based removal of 340B units from Part D inflation rebate math beginning January 1, 2026, plus a voluntary 340B repository for Part D claims (CMS PFS fact sheet).
- Part B inflation rebate guidance links shortage-based rebate reductions to drugs listed as currently in shortage on FDA shortage lists.
- FDA’s Feb 21, 2025 order declares the Wegovy/Ozempic semaglutide injection shortage resolved.
- Current Wegovy prescribing information covers weight management, CV risk reduction, and accelerated-approval MASH with F2–F3 fibrosis.
Why is 340B creating rebate uncertainty in 2026?
Under the Inflation Reduction Act, manufacturers owe inflation rebates when prices on certain Part B/D drugs rise faster than inflation. CMS’s CY 2026 PFS final-rule fact sheet says the agency is finalizing a claims-based method to strip 340B-acquired units out of Part D rebate calculations starting January 1, 2026.
CMS is also standing up a Medicare Part D Claims Data 340B Repository for voluntary covered-entity submissions on claims with dates of service on or after that date, initially for usability testing. Until repository data mature, manufacturers and covered entities will argue over residual misclassification risk—the core of Pharma Pulse 340B Uncertainty Drug debates in hospital pharmacy circles.
Hospital systems that rely on 340B savings for outpatient oncology and specialty pharmacy should model two 2026 scenarios: clean claims-based exclusion that reduces manufacturer Part D rebate exposure on 340B units, and noisy identification that leaves disputed units in rebate tallies. Dispute windows and data-sharing terms belong in MSA renewals now.
How do drug shortages change IRA rebate exposure?
CMS Part B inflation rebate guidance explains statutory authority to reduce or waive rebates when a Part B rebatable drug appears as currently in shortage on FDA CDER/CBER shortage lists during a calendar quarter. Statuses such as discontinued or resolved do not qualify.
That creates a mechanical link between FDA shortage listing decisions and manufacturer rebate ledgers. Supply-chain teams should coordinate shortage notifications with government-pricing groups so rebate models reflect list status in near real time.
Where does Wegovy sit after the shortage declaration?
FDA’s February 21, 2025 declaratory order recounts that Wegovy entered the shortage list in March 2022 and Ozempic in August 2022, then concludes the semaglutide injection shortage is resolved based on Novo Nordisk supply/demand submissions.
“Global debut” framing in older headlines should not override label facts: Wegovy is an established U.S. product with expanding indications. The August 2025 label highlights include CV risk reduction in adults with established CVD and obesity/overweight, chronic weight management in qualifying adults and adolescents 12+, and accelerated approval for noncirrhotic MASH with moderate-to-advanced fibrosis.
What should market-access teams do this quarter?
- Rebuild 2026 Part D inflation rebate forecasts excluding expected 340B units under the claims methodology.
- Map every NDC’s FDA shortage status to Part B rebate reduction eligibility each quarter.
- Separate Wegovy utilization models into weight, CV, and MASH cohorts using labeled populations.
- Avoid competitor hrefs when citing hospital-pharmacy sentiment; use CMS/FDA primaries.
What remains unproven
CMS has not, in the fact sheet cited here, published a finalized error rate for 340B unit identification in Part D. Voluntary repository testing in 2026 means early-year rebate invoices may still be contested. This article does not invent a new Wegovy country launch date beyond FDA labeling and shortage-resolution documents.
Related NovaPharma coverage
- Novo Nordisk supply of Wegovy stabilizes as FDA shortage ends
- Weight Loss Medications in 2026: GLP-1 Market Shift
- Opinion: Lawmakers Promised Cancer Patients Medicaid
Frequently Asked Questions
What 340B change did CMS finalize for 2026 Part D inflation rebates?
In the CY 2026 Medicare Physician Fee Schedule fact sheet, CMS finalized a claims-based methodology to remove 340B units from Part D inflation rebate calculations starting January 1, 2026, and established a voluntary Part D 340B claims repository for usability testing.
How do FDA drug shortages interact with IRA inflation rebates?
CMS Part B inflation rebate guidance allows reduction or waiver of rebate amounts when a rebatable drug is described as currently in shortage on FDA shortage lists under FD&C Act section 506E during the relevant quarter.
What is the FDA status of the Wegovy/semaglutide shortage?
FDA’s February 21, 2025 declaratory order states the semaglutide injection shortage (Wegovy and Ozempic) is resolved after review of manufacturer supply and demand data; Wegovy’s FDA label continues to expand indications including CV risk reduction and accelerated-approval MASH use.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for Wegovy.
Unlock full calendar →Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
